These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22677316)

  • 1. Identification of spirocyclic piperidine-azetidine inverse agonists of the ghrelin receptor.
    Kung DW; Coffey SB; Jones RM; Cabral S; Jiao W; Fichtner M; Carpino PA; Rose CR; Hank RF; Lopaze MG; Swartz R; Chen HT; Hendsch Z; Posner B; Wielis CF; Manning B; Dubins J; Stock IA; Varma S; Campbell M; DeBartola D; Kosa-Maines R; Steyn SJ; McClure KF
    Bioorg Med Chem Lett; 2012 Jul; 22(13):4281-7. PubMed ID: 22677316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of potent, selective, CNS-targeted inverse agonists of the ghrelin receptor.
    McClure KF; Jackson M; Cameron KO; Kung DW; Perry DA; Orr ST; Zhang Y; Kohrt J; Tu M; Gao H; Fernando D; Jones R; Erasga N; Wang G; Polivkova J; Jiao W; Swartz R; Ueno H; Bhattacharya SK; Stock IA; Varma S; Bagdasarian V; Perez S; Kelly-Sullivan D; Wang R; Kong J; Cornelius P; Michael L; Lee E; Janssen A; Steyn SJ; Lapham K; Goosen T
    Bioorg Med Chem Lett; 2013 Oct; 23(19):5410-4. PubMed ID: 23953189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and optimization of novel 4-[(aminocarbonyl)amino]-N-[4-(2-aminoethyl)phenyl]benzenesulfonamide ghrelin receptor antagonists.
    Pasternak A; Goble SD; deJesus RK; Hreniuk DL; Chung CC; Tota MR; Mazur P; Feighner SD; Howard AD; Mills SG; Yang L
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6237-40. PubMed ID: 19767208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-type calcium channel blockers: spiro-piperidine azetidines and azetidinones-optimization, design and synthesis.
    Smith EM; Sorota S; Kim HM; McKittrick BA; Nechuta TL; Bennett C; Knutson C; Burnett DA; Kieselgof J; Tan Z; Rindgen D; Bridal T; Zhou X; Jia YP; Dong Z; Mullins D; Zhang X; Priestley T; Correll CC; Tulshian D; Czarniecki M; Greenlee WJ
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4602-6. PubMed ID: 20580233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactive metabolite trapping studies on imidazo- and 2-methylimidazo[2,1-b]thiazole-based inverse agonists of the ghrelin receptor.
    Kalgutkar AS; Ryder TF; Walker GS; Orr ST; Cabral S; Goosen TC; Lapham K; Eng H
    Drug Metab Dispos; 2013 Jul; 41(7):1375-88. PubMed ID: 23610086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification, optimization, and pharmacology of acylurea GHS-R1a inverse agonists.
    McCoull W; Barton P; Brown AJ; Bowker SS; Cameron J; Clarke DS; Davies RD; Dossetter AG; Ertan A; Fenwick M; Green C; Holmes JL; Martin N; Masters D; Moore JE; Newcombe NJ; Newton C; Pointon H; Robb GR; Sheldon C; Stokes S; Morgan D
    J Med Chem; 2014 Jul; 57(14):6128-40. PubMed ID: 24967667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural Optimization of Ghrelin Receptor Inverse Agonists to Improve Lipophilicity and Avoid Mechanism-Based CYP3A4 Inactivation.
    Takahashi B; Funami H; Shibata M; Maruoka H; Koyama M; Kanki S; Muto T
    Chem Pharm Bull (Tokyo); 2015; 63(10):825-32. PubMed ID: 26423040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic.
    Hoveyda HR; Marsault E; Gagnon R; Mathieu AP; Vézina M; Landry A; Wang Z; Benakli K; Beaubien S; Saint-Louis C; Brassard M; Pinault JF; Ouellet L; Bhat S; Ramaseshan M; Peng X; Foucher L; Beauchemin S; Bhérer P; Veber DF; Peterson ML; Fraser GL
    J Med Chem; 2011 Dec; 54(24):8305-20. PubMed ID: 22106937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orally active ghrelin receptor inverse agonists and their actions on a rat obesity model.
    Takahashi B; Funami H; Iwaki T; Maruoka H; Shibata M; Koyama M; Nagahira A; Kamiide Y; Kanki S; Igawa Y; Muto T
    Bioorg Med Chem; 2015 Aug; 23(15):4792-4803. PubMed ID: 26100441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, evaluation, and comparison of ghrelin receptor agonists and inverse agonists as suitable radiotracers for PET imaging.
    Chollet C; Bergmann R; Pietzsch J; Beck-Sickinger AG
    Bioconjug Chem; 2012 Apr; 23(4):771-84. PubMed ID: 22372770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triazole oxytocin antagonists: Identification of an aryloxyazetidine replacement for a biaryl substituent.
    Brown A; Brown TB; Calabrese A; Ellis D; Puhalo N; Ralph M; Watson L
    Bioorg Med Chem Lett; 2010 Jan; 20(2):516-20. PubMed ID: 19963374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of the constitutive activity of the ghrelin receptor by use of pharmacological tools and mutagenesis.
    Mokrosiński J; Holst B
    Methods Enzymol; 2010; 484():53-73. PubMed ID: 21036226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ghrelin receptor inverse agonists: identification of an active peptide core and its interaction epitopes on the receptor.
    Holst B; Lang M; Brandt E; Bach A; Howard A; Frimurer TM; Beck-Sickinger A; Schwartz TW
    Mol Pharmacol; 2006 Sep; 70(3):936-46. PubMed ID: 16798937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ghrelin receptor: high constitutive activity and methods for developing inverse agonists.
    Els S; Beck-Sickinger AG; Chollet C
    Methods Enzymol; 2010; 485():103-21. PubMed ID: 21050913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ghrelin receptor modulators and their therapeutic potential.
    Costantino L; Barlocco D
    Future Med Chem; 2009 Apr; 1(1):157-77. PubMed ID: 21426074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological characterization of the first in class clinical candidate PF-05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose-dependent insulin secretion ex vivo.
    Kong J; Chuddy J; Stock IA; Loria PM; Straub SV; Vage C; Cameron KO; Bhattacharya SK; Lapham K; McClure KF; Zhang Y; Jackson VM
    Br J Pharmacol; 2016 May; 173(9):1452-64. PubMed ID: 26784385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ghrelin receptor modulators: a patent review (2011 - 2014).
    Costantino L; Barlocco D
    Expert Opin Ther Pat; 2014 Sep; 24(9):1007-19. PubMed ID: 25047815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An aromatic region to induce a switch between agonism and inverse agonism at the ghrelin receptor.
    Els S; Schild E; Petersen PS; Kilian TM; Mokrosinski J; Frimurer TM; Chollet C; Schwartz TW; Holst B; Beck-Sickinger AG
    J Med Chem; 2012 Sep; 55(17):7437-49. PubMed ID: 22920150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent achiral agonists of the growth hormone secretagogue (ghrelin) receptor. Part 2: Lead optimisation.
    Witherington J; Abberley L; Briggs MA; Collis K; Dean DK; Gaiba A; King NP; Kraus H; Shuker N; Steadman JG; Takle AK; Sanger G; Wadsworth G; Butler S; McKay F; Muir A; Winborn K; Heightman TD
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2203-5. PubMed ID: 18316188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delta agonist hydroxy bioisosteres: the discovery of 3-((1-benzylpiperidin-4-yl){4-[(diethylamino)carbonyl]phenyl}amino)benzamide with improved delta agonist activity and in vitro metabolic stability.
    Griffin AM; Brown W; Walpole C; Coupal M; Adam L; Gosselin M; Salois D; Morin PE; Roumi M
    Bioorg Med Chem Lett; 2009 Nov; 19(21):5999-6003. PubMed ID: 19800790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.